Statins, aspirin and risk of thromboembolic events in ovarian cancer patients

Gynecologic Oncology

Volumn 133, Issue 2, 2014, Pages 304-308

  Shai, Ayelet ^a   Rennert, Hedy S ^b   Rennert, Gad ^b   Sagi, Shlomi ^c   Leviov, Michelle ^a   Lavie, Ofer ^b  

^a CLALIT HEALTH SERVICES   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Aspirin; Deep vein thrombosis; Ovarian cancer; Pulmonary embolism; Statins; Venous thromboembolic events

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR RISK; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

ASPIRIN; DEEP VEIN THROMBOSIS; OVARIAN CANCER; PULMONARY EMBOLISM; STATINS; VENOUS THROMBOEMBOLIC EVENTS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; COHORT STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 84899631729     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.006     Document Type: Article

References (40)

1. C. Fotopoulou, A. duBois, A.N. Karavas, R. Trappe, B. Aminossadati, and B. Schmalfeldt et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group J Clin Oncol 26 16 2008 2683 2689 10.1200/JCO.2008.16.1109
2. L. Mereu, S. Tateo, C. Klersy, E. Martinotti Gabellotti, and F. Polatti Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy Int J Gynecol Cancer 19 1 2009 79 83 10.1111/IGJ.0b013e318199035e
3. F.A. Saadeh, L. Norris, S. O'Toole, and N. Gleeson Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival Eur J Obstet Gynecol Reprod Biol 170 1 2013 214 218 10.1016/j.ejogrb.2013.06.004
4. A. Bakhru Effect of ovarian tumor characteristics on venous thromboembolic risk J Gynecol Oncol 24 1 2013 52 58 10.3802/jgo.2013.24.1.52
5. J. Trujillo-Santos, J.M. Casas, I. Casado, A.L. Samperiz, R. Quintavalla, and J.C. Sahuquillo et al. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry Thromb Res 127 Suppl. 3 2011 S1 S4 10.1016/S0049-3848(11)00006-5
6. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, and B. Girolami et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 10 2002 3484 3488 10.1182/blood-2002-01-0108
7. A.L. Rodriguez, B.M. Wojcik, S.K. Wrobleski, D.D. Myers Jr., T.W. Wakefield, and J.A. Diaz Statins, inflammation and deep vein thrombosis: a systematic review J Thromb Thrombolysis 33 4 2012 371 382 10.1007/s11239-012- 0687-9
8. J.G. Ray, M. Mamdani, R.T. Tsuyuki, D.R. Anderson, E.L. Yeo, and A. Laupacis Use of statins and the subsequent development of deep vein thrombosis Arch Intern Med 161 11 2001 1405 1410
9. A.S. Ramcharan, K.J. Van Stralen, J.D. Snoep, A.K. Mantel-Teeuwisse, F.R. Rosendaal, and C.J. Doggen HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis J Thromb Haemost 7 4 2009 514 520 10.1111/j.1538-7836.2008.03235.x
10. C.J. Doggen, R.N. Lemaitre, N.L. Smith, S.R. Heckbert, and B.M. Psaty HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women J Thromb Haemost 2 5 2004 700 701 10.1111/j.1538-7836.2004.00696.x
11. K. Lacut, E. Oger, G. Le Gal, F. Couturaud, S. Louis, and C. Leroyer et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study Fundam Clin Pharmacol 18 4 2004 477 482 10.1111/j.1472-8206.2004.00252.x
12. D. Khemasuwan, Y.K. Chae, S. Gupta, A. Carpio, J.H. Yun, and S. Neagu et al. Dose-related effect of statins in venous thrombosis risk reduction Am J Med 124 9 2011 852 859 10.1016/j.amjmed.2011.04.019
13. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 18 2009 1851 1861 10.1056/NEJMoa0900241
14. L. Smeeth, I. Douglas, A.J. Hall, R. Hubbard, and S. Evans Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials Br J Clin Pharmacol 67 1 2009 99 109 10.1111/j.1365-2125.2008.03308.x
15. J. Hippisley-Cox, and C. Coupland Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database BMJ 340 2010 c2197 10.1136/bmj.c2197
16. C.C. Yang, S.S. Jick, and H. Jick Statins and the risk of idiopathic venous thromboembolism Br J Clin Pharmacol 53 1 2002 101 105
17. K. Rahimi, N. Bhala, P. Kamphuisen, J. Emberson, S. Biere-Rafi, and V. Krane et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials PLoS Med 9 9 2012 e1001310 10.1371/journal.pmed.1001310
18. C. Lopez-Pedrera, P. Ruiz-Limon, A. Valverde-Estepa, N. Barbarroja, and A. Rodriguez-Ariza To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer Curr Drug Targets 13 6 2012 829 841
19. U. Schonbeck, and P. Libby Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 21 Suppl. 1 2004 II18 II26 10.1161/01.CIR.0000129505.34151.23
20. J.N. Poynter, S.B. Gruber, P.D. Higgins, R. Almog, J.D. Bonner, and H.S. Rennert et al. Statins and the risk of colorectal cancer N Engl J Med 352 21 2005 2184 2192 10.1056/NEJMoa043792
21. I.L. Beales, I. Vardi, and L. Dearman Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma Eur J Gastroenterol Hepatol 24 8 2012 917 923 10.1097/MEG.0b013e3283543f01
22. S.W. Marcella, A. David, P.A. Ohman-Strickland, J. Carson, and G.G. Rhoads Statin use and fatal prostate cancer: a matched case-control study Cancer 118 16 2012 4046 4052 10.1002/cncr.26720
23. O. Lavie, M. Pinchev, H.S. Rennert, Y. Segev, and G. Rennert The effect of statins on risk and survival of gynecological malignancies Gynecol Oncol 130 3 2013 615 619 10.1016/j.ygyno.2013.05.025
24. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial Lancet 355 9212 2000 1295 1302
25. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 7329 2002 71 86
26. C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, and M. Silingardi et al. Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 366 21 2012 1959 1967 10.1056/NEJMoa1114238
27. A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano, and F. Patriarca et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial J Clin Oncol 29 8 2011 986 993 10.1200/JCO.2010.31.6844
28. A. Larocca, F. Cavallo, S. Bringhen, F. Di Raimondo, A. Falanga, and A. Evangelista et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 4 2012 933 939 10.1182/blood-2011-03-344333 [quiz 1093]
29. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, and B. Brenner et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J Thromb Haemost 11 1 2013 56 70 10.1111/jth.12070
30. D. Khemasuwan, M.L. Divietro, K. Tangdhanakanond, S.C. Pomerantz, and G. Eiger Statins decrease the occurrence of venous thromboembolism in patients with cancer Am J Med 123 1 2010 60 65 10.1016/j.amjmed.2009.05.025
31. M. Charlson, T.P. Szatrowski, J. Peterson, and J. Gold Validation of a combined comorbidity index J Clin Epidemiol 47 11 1994 1245 1251
32. K.A. Patterson, X. Zhang, S.K. Wrobleski, A.E. Hawley, D.A. Lawrence, and T.W. Wakefield et al. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects Thromb Res 131 3 2013 268 276 10.1016/j.thromres.2012.12.006
33. A. Falanga, and S.G. Gordon Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue Biochemistry 24 20 1985 5558 5567
34. A.K. Kakkar, N. DeRuvo, V. Chinswangwatanakul, S. Tebbutt, and R.C. Williamson Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor Lancet 346 8981 1995 1004 1005
35. A. Shai, H.S. Rennert, O. Lavie, M. Ballan-Haj, A. Bitterman, and M. Steiner et al. Statins, aspirin and risk of venous thromboembolic events in breast cancer patients J Thromb Thrombolysis 2013 10.1007/s11239-013-1015-8
36. L. Rabinowich, A. Steinvil, E. Leshem-Rubinow, S. Berliner, D. Zeltser, and O. Rogowski et al. Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation Heart 98 24 2012 1817 1821 10.1136/heartjnl-2012-302906
37. S.F. Nielsen, B.G. Nordestgaard, and S.E. Bojesen Statin use and reduced cancer-related mortality N Engl J Med 367 19 2012 1792 1802 10.1056/ NEJMoa1201735
38. R.G. Elmore, Y. Ioffe, D.R. Scoles, B.Y. Karlan, and A.J. Li Impact of statin therapy on survival in epithelial ovarian cancer Gynecol Oncol 111 1 2008 102 105
39. P.M. Rothwell, M. Wilson, J.F. Price, J.F. Belch, T.W. Meade, and Z. Mehta Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 9826 2012 1591 1601 10.1016/S0140-6736(12)60209-8
40. P.M. Rothwell, J.F. Price, F.G. Fowkes, A. Zanchetti, M.C. Roncaglioni, and G. Tognoni et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 9826 2012 1602 1612 10.1016/S0140-6736(11)61720-0